Vis børsmeldingen
investigating the ability of Betalutin® (177Lu-lilotomab satetraxetan) to
reverse rituximab-resistance in disease models of non-Hodgkin’s lymphoma (NHL)
has been published in the October 2020 issue of The Journal of Nuclear Medicine
(M. Malenge et al*).
NHL is the most common blood cancer and has a high mortality rate. The CD20
-targeting monoclonal antibody immunotherapy rituximab was approved for
treatment of NHL more than 20 years ago and is the current standard of care.
However, many patients eventually develop resistance against rituximab, which is
often associated with changes (a decrease) in expression of the CD20 antigen on
NHL cells.
The study found that:
· Betalutin® (an anti-CD37 radioimmunoconjugate) acted synergistically with
rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab
-resistant xenograft NHL mouse model.
· The median survival time of mice treated with this combination doubled when
compared to survival of mice given Betalutin® monotherapy and was five times
longer than for mice given rituximab monotherapy.
· In NHL cell lines, Betalutin® was found to substantially increase CD20
expression and rituximab binding to rituximab-resistant Raji2R cells and to
increase rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC)
activity, resulting in significant tumor growth delay.
“This work is potentially very important, as it could provide a welcome
treatment option for the large pool of NHL patients who have become resistant to
rituximab. If those patients receive an injection of Betalutin®, they could be
treated again with rituximab and have an improved response,” said Dr Jostein
Dahle, Chief Scientific Officer of Nordic Nanovector. “In a Phase 1b clinical
trial, a 100 percent complete response rate was achieved in the first group of
patients treated with Betalutin® followed by rituximab. Achieving a complete
response is very important as it usually correlates with an improved duration of
response and overall survival.”
Dr Dahle continued, “Combination treatments are the future for cancer therapy.
By exploring strategies with radioimmunotherapy together with other drugs,
nuclear medicine may play an important role in lymphoma therapy.”
*Reference
M. Malenge et al. 177Lu-Lilotomab Satetraxetan has the Potential to Counteract
Resistance to Rituximab in Non-Hodgkin’s Lymphoma. J. Nuclear. Med. (2020)
61/10/1468
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine,
molecular imaging and theragnostic journal, accessed close to 10 million times
each year by practitioners around the globe, providing them with the information
they need to advance this rapidly expanding field. Current and past issues of
The Journal of Nuclear Medicine can be found online at
http://jnm.snmjournals.org
JNM is published by the Society of Nuclear Medicine and Molecular Imaging
(SNMMI), an international scientific and medical organization dedicated to
advancing nuclear medicine and molecular imaging-precision medicine that allows
diagnosis and treatment to be tailored to individual patients in order to
achieve the best possible outcomes. For more information, visit www.snmmi.org.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.
Kilde
Eller er det kanskje motsatt nok en gang; når aksjemarkedet er blottet for tillit til hva som kan forventes av hyggelige ting, det er da man skal gå long og ikke ut?
” med full skivebom.
